CLINICAL STUDIES/TRIALS

这项临床研究/试验项目是基于 过去几年，并继续支持两项主要倡议(1) “肺”区域灌注强化化疗 软组织肉瘤转移至肺的患者。(2)临床前 以及高危STS患者的临床免疫学研究。在第1a条中， 第一阶段和第二阶段试验正在进行中，并计划进行。组织来源： 这些研究中的患者将被送往项目1b、2和 3用于分析肿瘤抗原、细胞周期调节因子及其作用机制 抗药性。在1b节，计划进行临床前研究以确定 为了延缓肿瘤疫苗的发展而开发的新方法 或阻止疾病的发展。对潜在目标知之甚少 在STS上，除神经节苷脂和SYT_SSX融合蛋白外，均在 在这个项目中学习。因此，我们计划识别抗原 通过筛选来自自体肿瘤的DNA文库表达， SYT_SSX融合多肽和DNA免疫研究 蛋白质，并评估针对组合的免疫 高危患者的神经节苷脂。 ？

This Clinical Studies/Trials Project is based on accomplishment over the past several years and continues to support two major initiatives (1) intensification of chemotherapy by regional Infusion" of the lung for patients with Soft Tissue Sarcoma metastatic to the lung. (2) Preclinical and clinical immunologic studies of high risk STS patients. In section 1a, phase I and phase II trials are ongoing and planned. Tissue obtained from patients in these studies will be sent to investigators in project 1b, 2, and 3 for analysis of tumor antigens, cell cycle regulators and mechanisms of drug resistance. In section 1b, preclinical studies are planned to define novel approaches for the development of tumor vaccines in order to delay or prevent progression of disease. Little is known about potential target on STS, except gangliosides and SYT_SSX fusion proteins, both under study in this Program Project. Therefore, we plan to identify antigens expressed by screening DNA libraries derived from autologous tumors, investigate peptide and DNA immunization against SYT_SSX fusion proteins, and evaluate immunizations against combinations of gangliosides in high risk patients. ?